Danish pharmaceutical giant Novo Nordisk is introducing a new subscription-based pricing model for patients who purchase their weight loss drug Wegovy without insurance coverage, providing monthly cost reductions of nearly 30% compared to standard pricing as the company works to expand market access and compete with rival Eli Lilly in the rapidly expanding obesity medication sector.
The competitive landscape for self-paying obesity drug customers is intensifying as both Novo Nordisk and Eli Lilly pursue direct-to-consumer sales strategies and partner with telehealth companies to attract patients, discourage use of compounded alternatives, and promote long-term treatment adherence – despite concerns that aggressive price reductions could impact profit margins.
Industry experts and financial analysts suggest Novo Nordisk may be at a disadvantage in this pricing competition, having implemented steeper cost cuts than Lilly in an effort to boost prescription numbers that have fallen behind Lilly’s competing medication Zepbound.
Starting Tuesday, the subscription program will be accessible through telehealth services such as Ro, WeightWatchers and LifeMD, allowing qualifying self-paying customers to purchase three-, six- or twelve-month medication supplies at set monthly rates, with extended plans providing greater savings. Additional telehealth providers including Hims & Hers and Sesame are expected to participate shortly, according to Novo Nordisk.
The Danish manufacturer underwent significant changes last year, including CEO replacement, substantial workforce reductions, and appointment of new U.S. division leadership, as part of efforts to strengthen its competitive position against Lilly, which rapidly established direct consumer sales channels.
Ed Cinca, who serves as Novo Nordisk’s senior vice president of marketing and patient solutions, explained that consumers are seeking “easier and clearer ways of facilitating payment” for obesity treatment options.
“We’re seeing the patient evolving into the consumer of health,” Cinca stated, noting that individuals paying directly want straightforward budgeting options, transparent pricing, and simplified methods to continue their treatment regimens.
The subscription structure sets Wegovy injection pen costs at $329 monthly for three-month plans, $299 for six-month options, and $249 for twelve-month subscriptions – representing savings of 6% to 29% below the current $349 monthly standard price.
Wegovy pill form pricing will be $289, $269, and $249 monthly respectively, offering approximately 3% to 17% reductions from the standard $299 monthly cost.
Eli Lilly’s direct-pay pricing for Zepbound begins at $299 monthly for the 2.5 mg dosage, $399 for 5 mg, and $449 for 7.5 mg and higher strengths through its “Self Pay Journey Program.”
Lilly’s competing oral obesity medication awaits U.S. Food and Drug Administration review, with company officials anticipating second-quarter approval. Previous reports indicated potential April approval timing.
Market competition has escalated as both pharmaceutical companies attempt to direct patients toward their branded, FDA-approved medications and away from less expensive compounded alternatives.
Zach Reitano, chief executive of telehealth company Ro, which partners with Novo Nordisk, observed that both Novo and Lilly are exploring innovative customer outreach methods, resulting in reduced drug prices and lower distribution expenses.
“They’re following the exact same path that you’d normally see in other consumer industries,” Reitano commented.
Novo Nordisk is increasingly relying on telehealth partnerships and direct distribution methods to connect with self-paying patients, representing a departure from conventional insurance-based channels and traditional physician office visits.
In November, Novo Nordisk reduced Wegovy’s standard monthly self-pay cost to $349 from $499, approximately a 30% decrease, following introduction of a temporary $199 starter-dose promotion.
